This antibody is designed, produced, and validated as part of a collaboration between Rockland and the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. Anti-UPLC1 (up-regulated in liver cancer 1) / ASAP3 Antibody, also named DDEFL1 (development and differentiation-enhancing factor-like 1) or ASAP3, is a member of the AZAP family of proteins. These proteins catalyze the hydrolysis of GTP bound to ADP-ribosylation factor (Arf) proteins, thereby causing Arf inactivation. For this reason, the ASAPs are generally called ArfGAPs. The activity of ArfGAPs is dependent on the presence of phosphoinositides and is implicated in cellular processes such as membrane trafficking and remodeling of the actin cytoskeleton. ASAP3 has been found to be up-regulated in 80% of the hepatocellular carcinomas examined. Initial biochemical characterization reveals that ASAP3 shows class-specific GAP activity on Arf proteins, preferring Arf5 over Arf1 and Arf6. ASAP3 antibody has beed developed through the NCI antibody collaboration program and is ideal for Cancer and Signal Transduction research.
ASAP3 Antibody, Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 3, FLJ20199 antibody,
This antibody was prepared from whole rabbit serum produced by repeated immunizations with recombinant human UPLC1/ASAP3 protein.